Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Affected Halt

<< Previous

Bullboard Posts

Next >>

Comment by Theknocker91on May 19, 2020 2:20pm

172 Views

Post# 31047209

RE:RE:RE:Affected Halt

If the stock unhalted today I can guarantee it would hit 0.005. We all gave them one last chance and it is clear without a doubt who these people are now. Shareholders will never be rewarded. This is a company that just continually dilutes. There is absolutely no reason they couldn't have found non dilutive financing for phase 3 if the product is as good as they say. If their own K-1012 treatment for ARDS was actually a thing then they wouldn't have bought this nitric oxide treatment from salzman. And they couldve gotten it fast tracked or even grants given the urgency. There just aren't any more excuses for them. It is over for shareholders.

<< Previous

Bullboard Posts

Next >>

New Pacific Metals delivers robust Silver Sand pre-feasibility study